Recently, analysts have boosted the average one-year price target for Vera Therapeutics (NasdaqGM:VERA) to a commanding 31.47 per share. This impressive revision marks a notable 30.61% upswing from the previous estimate of 24.10, dated January 16, 2024.
Reflecting a congregation of insights, the new price target encompasses an array of projections from analysts. Among these estimations, the spectrum ranges from a modest 21.21 to a lofty 52.50 per share. At this juncture, the average price target signifies a 33.67% decrease from the recent closing price of 47.45 per share.
The Heartbeat of Fund Sentiment
Presently, 226 funds or institutions stand as proud custodians of Vera Therapeutics. This count illustrates an upsurge of 17 new stakeholders, marking an 8.13% rise within the last quarter. The average portfolio weight of these proponents for VERA stands at a commendable 0.17%, reflecting a 1.20% growth surge.
Among the investing elite, the total institutional shares surged upward by 6.10% over the recent three months, vaulting to 43,161K shares. Emphasizing the sentiment, the put/call ratio for VERA stands at 2.92, denoting a bearish inclination.
A Glimpse Into Shareholder Realm
Commendably, Commodore Capital retains ownership of 5,450K shares, which accounts for a formidable 10.38% stake within the company. Notably, there have been no alterations in this stronghold over the past quarter.
Kynam Capital Management exhibits a solid grip on 3,650K shares, wielding a 6.95% ownership. In a notable revelation, the firm has bolstered its allegiance by amplifying its shareholding from 2,956K shares – signifying a robust 19.02% upsurge. Despite this, the portfolio weight has seen a slight dip of 6.17% in the last quarter.
Sofinnova Investments anchors its position with 3,467K shares, accounting for 6.60% ownership, holding steadfast with no adjustments in the past quarter. Similarly, Woodline Partners maintains a 4.78% share through 2,507K shares. Although the firm has downsized from its prior 2,563K shares, witnessing a 2.21% decline, it has matured its portfolio stake by 1.81% over the preceding quarter.
Steering their strategy, Eversept Partners holds 1,915K shares, representing a 3.65% ownership. Over the last filing, the firm flaunted a growth spurt, ascending from 1,478K shares – showcasing a remarkable 22.79% escalation. In a bold move, the entity augmented its portfolio allocation by a striking 50.84% in the past quarter.
Fintel stands tall as a haven for investors, providing comprehensive resources for individual investors, financial advisors, and hedge funds alike. Packed with global data on fundamentals, analyst reports, ownership figures, and even options sentiment, Fintel offers a treasure trove of insights and analytics for navigating the financial realm with finesse.
Discover more on Fintel and unveil the riches of market wisdom it holds.
This article was initially published on Fintel.
The musings and opinions reflected here are solely those of the author and may not necessarily echo the sentiments of Nasdaq, Inc.
